 |
|
|  | |||||||||||||||||||||||||||||||||||||
| Sort by relevance Sorted by date |
Teva signs deal with Andrx, Impax on stop-smoking drugs
Globes Online, Israel - 3 hours ago
... reached an agreement with US drug makers Andrx (Nasdaq: ADRX) and Impax (Nasdaq:
IPXL) on the launch of the generic version of GlaxoSmithKline’s Wellbutrin ...
TASE may remain stagnant after Nasdaq drop
Globes Online, Israel - 5 hours ago
... that it reached an agreement with Andrx (Nasdaq: ADRX) and Impax (Nasdaq: IPXL)
on the launch of the generic version of GlaxoSmithKline’s Wellbutrin and ...
US Generic Competition Nears on Glaxo Drugs
Reuters, UK - Jul 31, 2003
... that would allow Impax to market its generic versions of antidepressant Wellbutrin
SR and smoking cessation drug Zyban even if Andrx got approval for its ...
Impax signs deal with rival
East Bay Business Times, CA - Jul 31, 2003
... with Andrx Corp. regarding generic forms of the popular antidepressant
Wellbutrin SR and smoking cessation drug Zyban. Included in ...
Thursday's East Bay Biz Buzz
Contra Costa Times, CA - Jul 31, 2003
... Andrx Corp., stymied in its efforts to win regulatory approval to sell a generic
copy of the Wellbutrin antidepressant, signed an agreement with rivals Impax ...
Thursday's East Bay Biz Buzz
Contra Costa Times, CA - Jul 31, 2003
... Andrx Corp., stymied in its efforts to win regulatory approval to sell a generic
copy of the Wellbutrin antidepressant, signed an agreement with rivals Impax ...
Teva Signs Agreement with Andrx and IMPAX for Generic ...
Business Wire (press release) - Jul 31, 2003
... (NASDAQ NM:IPXL) pertaining to pending Abbreviated New Drug Applications (ANDAs)
for bioequivalent versions of Wellbutrin(R) SR and Zyban(R) (Bupropion ...
IMPAX Signs Agreement with Andrx and Teva for Generic ...
Business Wire (press release) - Jul 31, 2003
... (NASDAQ:TEVA) pertaining to pending Abbreviated New Drug Applications (ANDAs)
for bioequivalent versions of Wellbutrin(R) SR and Zyban(R) (Bupropion ...
Andrx Signs Agreement with Impax and Teva for Generic ...
Business Wire (press release) - Jul 31, 2003
(Nasdaq:TEVA) pertaining to pending Abbreviated New Drug Applications (ANDAs)
for bioequivalent versions of Wellbutrin(R) SR and Zyban(R) (Bupropion ...
Long-Term Drug
Mind Horizons, TX - Jul 31, 2003
... bipolar disorder. Three pharmaceutical companies contributed free drugs,
including Glaxo's Wellbutrin and Pfizer Inc.'s Zoloft. The ...
Cops had prior problems with former deputy charged in murder-for ...
King County Journal, WA - Jul 31, 2003
... Court records indicate he was regularly taking 40 milligrams twice a day of the powerful
painkiller Oxycontin, as well as daily doses of Prozac, Wellbutrin and ...
Cops had prior problems with former deputy charged in murder-for ...
King County Journal Newspapers, WA - Jul 31, 2003
... Court records indicate he was regularly taking 40 milligrams twice a day of the powerful
painkiller Oxycontin, as well as daily doses of Prozac, Wellbutrin and ...
Biovail slumps as Street backs away
The Globe and Mail, Canada - Jul 31, 2003
... Sources also attributed part of the weakness yesterday to speculation about a
possible generic launch of a twice-daily Wellbutrin SR before Biovail and ...
Biovail slumps as Street backs away
The Globe and Mail, Canada - Jul 31, 2003
... Sources also attributed part of the weakness yesterday to speculation about a
possible generic launch of a twice-daily Wellbutrin SR before Biovail and ...
Buy CVS Corp .
BusinessWeek - Jul 30, 2003
... S&P expect second-half earnings per share to exceed the first half, boosted by new
products (possibly generic Wellbutrin SR), and manufacturing efficiencies. ...
UPDATE 2-Andrx posts second straight profitable quarter
Reuters, UK - Jul 30, 2003
... said it is working with the US Food and Drug Administration to gain final clearance
to sell generic versions of GlaxoSmithKline Plc GSK.L drugs Wellbutrin SR ...
Andrx Corporation Reports 2003 Second Quarter Results
Business Wire (press release) - Jul 30, 2003
... We are also continuing to work on our Wellbutrin SR(R) and Zyban(R) products, and
remain confident that we will be able to commercialize the value of our ANDAs ...
Biovail shares hit on poor results
The Globe and Mail, Canada - Jul 30, 2003
... The true profitability of the overall business is below trendline" and two new
drug launches this year, Cardizem LA and Wellbutrin XL, will now have to ...
Biovail shares hit on poor results
The Globe and Mail, Canada - Jul 30, 2003
... The true profitability of the overall business is below trendline" and two new
drug launches this year, Cardizem LA and Wellbutrin XL, will now have to ...
Biovail sales set record
Toronto Star, Canada - Jul 29, 2003
... Wellbutrin XL, a once-daily anti-depressant, "should contribute to strong
organic growth for Biovail in the coming quarters," Melnyk added. ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
Waterloo Record (subscription), Canada - Jul 29, 2003
... Biovail's big successes for the quarter were the US FDA approval for the sale of
Wellbutrin XL, a once-daily anti-depressant, south of the boarder in the fall ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
CBC News, Canada - Jul 29, 2003
... Biovail's big successes for the quarter were the US FDA approval for the sale of
Wellbutrin XL, a once-daily anti-depressant, south of the boarder in the fall ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
CJAD, Canada - Jul 29, 2003
... Biovail's big successes for the quarter were the US FDA approval for the sale of
Wellbutrin XL, a once-daily anti-depressant, south of the boarder in the fall ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
Canada.com, Canada - Jul 29, 2003
... Biovail's big successes for the quarter were the US FDA approval for the sale of
Wellbutrin XL, a once-daily anti-depressant, south of the boarder in the fall ...
UPDATE 4-Biovail posts loss, drug sales below forecast
Reuters, UK - Jul 29, 2003
... Analysts said things should improve for the company as it gets ready
to market Wellbutrin XL, a once daily drug for depression. ...
UPDATE 3-Biovail makes loss, drug sales fall below forecast
Reuters, UK - Jul 29, 2003
... But some analysts said things would improve for the company as it gets
ready to market Wellbutrin XL, a once daily drug for depression. ...
Biovail Q2 net loss $1M US
Toronto Star, Canada - Jul 29, 2003
... Wellbutrin XL, a once-daily anti-depressant, "should contribute to strong
organic growth for Biovail in the coming quarters," Melnyk added. ...
Writeoffs tarnish strong quarter for Biovail
Ottawa Business Journal, Canada - Jul 29, 2003
... to $217.3 million from $185.1 million thanks to the launch of Biovail's Cardizem
heart drug in April and the strength of anti-depression treatment Wellbutrin XL ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
Ottawa Citizen, Canada - Jul 29, 2003
... Wellbutrin XL, a once-daily anti-depressant, "should contribute to strong
organic growth for Biovail in the coming quarters," Melnyk added. ...
UPDATE 2-Acquisition costs cause Biovail loss but sales up
Reuters, UK - Jul 29, 2003
... The company said contributions from Wellbutrin XL, used to treat depression, also
boosted results as the drug received an approvable letter from the US Food ...
Biovail Q2 net loss $1M US after $84.2M item; revenue up 17% to ...
Canada.com, Canada - Jul 29, 2003
... Wellbutrin XL, a once-daily anti-depressant, "should contribute to strong
organic growth for Biovail in the coming quarters," Melnyk added. ...
MOVERS & SHAKERS
CBS MarketWatch - Jul 29, 2003
... Biovail said results were helped by the launch of its Cardizem LA product in April,
contributions from Wellbutrin XL, growth from Canadian product sales and an ...
Biovail sales rise 17%
The Globe and Mail, Canada - Jul 29, 2003
... earnings-per-share guidance — said, was the launch of its Cardizem LA treatment
in April and contributions from its anti-depression treatment Wellbutrin XL ...
Biovail Reports Record Second Quarter 2003 Financial Results
Business Wire (press release) - Jul 29, 2003
Contributing to these favorable results was the launch of Cardizem LA in April 2003,
contributions from Wellbutrin XL, which received an Approvable Letter in ...
Bitter Orange Could Mean Red Alert With Some Drugs
Newsday - Jul 29, 2003
... effects. Q. I've been taking Wellbutrin and Remeron for severe depression.
But lately I've developed paranoid thoughts and feelings. ...
How Do You Get Work Done?
Slashdot - Jul 27, 2003
... be. A *lot* alike. What worked for me? Wellbutrin and/or Effexor.
I wasn't depressed, and I really wasn't an ADD type. Although ...
How Biovail keeps growing
Toronto Star, Canada - Jul 24, 2003
... Human Services in a set of guidelines issued in April — Biovail is moving on to
its next promising relaunch of a mature drug, the anti-depressant Wellbutrin. ...
GlaxoSmithKline's quarterly profit rises
Seattle Post Intelligencer, WA - Jul 24, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Slower sales fail to curb GSK profits
The Times, UK - Jul 23, 2003
... Levitra, a treatment for impotence, is already on sale in Europe, while Wellbutrin,
an antidepressant, is expected to be approved by US authorities in September ...
Glaxo Q2 net up 9%, eyes better '03
Economic Times, India - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Biovail, GSK get good news on Wellbutrin
Raleigh Triangle Business Journal, NC - Jul 23, 2003
The US Food and Drug Administration will probably make a decision by early September
on whether or not to approve Wellbutrin XL, which GlaxoSmithKline has ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update4)
Bloomberg - Jul 23, 2003
... Glaxo has so far been able to fend off generic competition for Paxil
and another depression drug, Wellbutrin. This year, Glaxo plans ...
GlaxoSmithKline on a high
News24, South Africa - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Drug developer GlaxoSmithKline's quarterly profit rises 13 per ...
Waterloo Record, Canada - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
UPDATE 2-Drugmakers sales slow down due to rival medicines
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Big Drugmakers Lose Sales to Rivals
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Big Drugmakers Lose Sales to Rivals
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline's Quarterly Profit Rises
Springfield News Sun, OH - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Big Drugmakers Losing Sales to Rivals
FOX News - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
CORRECTED - Drugmakers sales slow down due to rival medicines
Forbes - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Drugmakers sales slow down due to rival medicines
Forbes - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update3)
Bloomberg - Jul 23, 2003
... Glaxo has so far been able to fend off generic competition for Paxil
and another depression drug, Wellbutrin. This year, Glaxo plans ...
CORRECTED - Drugmakers sales slow down due to rival medicines
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline's Quarterly Profit Rises
Atlanta Journal Constitution, GA - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
Austin American Statesman, TX - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Drug developer GlaxoSmithKline's quarterly profit rises 13 per ...
Canada.com, Canada - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
San Jose Mercury News, CA - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
Newsday - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Big Drugmakers Losing Sales to Rivals
Washington Post, DC - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline's quarterly profit rises
Penn Live, PA - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL. ...
GlaxoSmithKline's Quarterly Profit Rises
Kansas City Star, MO - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
Times Daily, AL - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
Fort Wayne News Sentinel, IN - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
GlaxoSmithKline's Quarterly Profit Rises
Miami Herald, FL - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Drugmakers sales slow down due to rival medicines
Forbes - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline's Quarterly Profit Rises
Sarasota Herald-Tribune, FL - Jul 23, 2003
... drug Levitra, developed by Germany's Bayer AG and marketed by GlaxoSmithKline, hit
the market by the end of the year, along with anti-depressant Wellbutrin XL.
Big Drugmakers Losing Sales to Rivals
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Drugmakers sales slow down due to rival medicines
Forbes - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Big Drugmakers Losing Sales to Rivals
Reuters, UK - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
Big Drugmakers Losing Sales to Rivals
MSN Money - Jul 23, 2003
... The London-based firm raised its 2003 forecast due to delays in the US launch of
generic rivals to its antidepressants, Paxil and Wellbutrin, analysts said. ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update3)
Bloomberg - Jul 23, 2003
... Glaxo has so far been able to fend off generic competition for Paxil
and another depression drug, Wellbutrin. This year, Glaxo plans ...
UPDATE 4-Glaxo raises guidance after strong Q2, shares gain
Reuters, UK - Jul 23, 2003
... Many analysts had felt that was overly conservative given delays in the arrival
of generic forms of another antidepressant, Wellbutrin, and the likelihood ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update2)
Bloomberg - Jul 23, 2003
... company said. Glaxo has so far been able to fend off generic competition
for Paxil and another depression drug, Wellbutrin. Shares ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update1)
Bloomberg - Jul 23, 2003
... company said. Glaxo has so far been able to fend off generic competition
for Paxil and another depression drug, Wellbutrin. Shares ...
Glaxo 2nd-Qtr Net Rises 13% on Higher Sales of Advair (Update4)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
Glaxo 2nd-Qtr Net Rises 13% on Higher Sales of Advair (Update4)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
GlaxoSmithKline, Roche Raise Estimates on Drug Sales (Update2)
Bloomberg - Jul 23, 2003
... company said. Glaxo has so far been able to fend off generic competition
for Paxil and another depression drug, Wellbutrin. Shares ...
Impotence drug perks up Glaxo prospects
The Times, UK - Jul 23, 2003
... GSK and partner Mayer believe. Wellbutrin XL, an anti-depressant, should
win US approval in the autumn. However, the company noted ...
Glaxo's Profit Climbs
Smart Money - Jul 23, 2003
... company said it is on track to launch two key products into the US market in the
second half of the year -- Levitra for erectile dysfunction, and Wellbutrin XL ...
Glaxo 2nd-Qtr Net Rises 13% on Higher Sales of Advair (Update3)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
Glaxo 2nd-Qtr Net Rises 13% on Higher Sales of Advair (Update3)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
Biovail Confirms FDA Class I Status for Wellbutrin XL Submission
Business Wire (press release) - Jul 23, 2003
... BUSINESS WIRE)--July 23, 2003--Biovail confirmed today that the US Food and Drug
Administration (FDA) has classified the recent response to the Wellbutrin XL ...
Glaxo Earns Beat Forecasts, Shares Climb
Reuters, UK - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
UPDATE 2-Glaxo Q2 earnings beat forecasts, shares climb
Reuters, UK - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Glaxo posts 9% gain in 2Q profit
CNN/Money - Jul 23, 2003
... however, have argued for some time that it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Glaxo 2nd-Qtr Net Rose 13% on Higher Sales of Advair (Update2)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
Glaxo 2nd-Qtr Net Rose 13% on Higher Sales of Advair (Update2)
Bloomberg - Jul 23, 2003
... was rejected by shareholders in May, was able to boost the earnings outlook for
this year by protecting patents for the antidepressants Paxil and Wellbutrin ...
Glaxo Earns Beat Forecasts, Shares Climb
Washington Post, DC - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Shares rise 4 percent in London
CBS MarketWatch - Jul 23, 2003
... 1 whether the Food and Drug Administration would approve Wellbutrin
XL. Emily Church is London bureau chief of CBS.MarketWatch.com.
Glaxo Earns Beat Forecasts, Shares Climb
Reuters, UK - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Glaxo earnings beat forecasts
... Analysts, however, have argued for some time it had room to edge up guidance folloiwing
delays in the US generic launch of another antidepressant, Wellbutrin. ...
Glaxo Earns Beat Forecasts, Shares Climb
MSN Money - Jul 23, 2003
... Analysts, however, have argued for some time it had room to edge up guidance following
delays in the US generic launch of another antidepressant, Wellbutrin. ...
European drug leader Glaxo faces Q2 currency drag
Forbes - Jul 23, 2003
... are still hoping GSK will upgrade its earnings guidance for 2003, since the widely
anticipated launch of a generic version of antidepressant Wellbutrin in the ...
Biovail says research and others say conflict
The Globe and Mail, Canada - Jul 22, 2003
... Still, the company's shares are up by close to 100 per cent in the past year,
as a result of optimism about sales of its new antidepressant, Wellbutrin XL ...
Biovail says research and others say conflict
The Globe and Mail, Canada - Jul 22, 2003
... Still, the company's shares are up by close to 100 per cent in the past year,
as a result of optimism about sales of its new antidepressant, Wellbutrin XL ...
Biovail is in hot water — again
The Globe and Mail, Canada - Jul 21, 2003
... Still, the company's shares are up by close to 100 per cent in the past year, as
a result of optimism about sales of its new anti-depressant Wellbutrin, which ...
Glaxo CEO Garnier Tries to Prop Up Profits Amid Pay Scrutiny
Bloomberg - Jul 20, 2003
... The company also plans to introduce this year a longer- lasting version of its Wellbutrin
anti-depressant, a $1.4 billion seller last year that faces generic ...
Glaxo CEO Garnier Tries to Prop Up Profits Amid Pay Scrutiny
Bloomberg - Jul 20, 2003
... The company also plans to introduce this year a longer- lasting version of its Wellbutrin
anti-depressant, a $1.4 billion seller last year that faces generic ...
Drugs giants find generic competition a bitter pill to swallow
Scotland on Sunday, UK - Jul 19, 2003
... Nevertheless, it has not been all bad news for Glaxo: the delay of the launch of
a generic version of its antidepressant Wellbutrin in the US has provided some ...
|
| Google Home - Advertise with Us - Business Solutions - Services & Tools - Jobs, Press, & Help |
